Sensorion SA (EPA:ALSEN)
France · Delayed Price · Currency is EUR | Market Cap | 73.37M -22.5% |
| Revenue (ttm) | 6.16M +9.0% |
| Net Income | -34.13M |
| EPS | -4.37 |
| Shares Out | 10.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,540 |
| Open | 7.85 |
| Previous Close | 7.85 |
| Day's Range | 7.09 - 7.97 |
| 52-Week Range | 7.09 - 40.40 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 40.20 (+464.61%) |
| Est. Earnings | Dec 24, 2026 |
About Sensorion
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural... [Read more]
Financial Performance
In 2025, Sensorion's revenue was 5.81 million, a decrease of -12.61% compared to the previous year's 6.65 million. Losses were -29.43 million, 13.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ALSEN stock is "Strong Buy." The 12-month stock price target is €40.20, which is an increase of 464.61% from the latest price.
News
Sensorion Earnings release: H1 2026
Sensorion released its H1 2026 earnings on September 23, 2026, summarizing the period's financial results.
Sensorion Quarterly report: H1 2026
Sensorion has published its H1 2026 quarterly earnings report on September 23, 2026.
Sensorion Transcript: Status update
SENS-601, a gene therapy for GJB2-related hearing loss, has entered clinical development with first patient dosing targeted for early 2027. Supported by strong preclinical data and fast-track approval in France, the trial focuses on early intervention, binaural hearing restoration, and key endpoints of safety, tolerability, and hearing improvement.
Sensorion Slides: Status update
Sensorion has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Sensorion Secures ANSM Approval To Launch Phase I/II HearConnex Trial Of SENS-601 In France
(RTTNews) - Sensorion SA (ALSEN.PA), a clinical-stage biotechnology company, announced that it has received authorisation from the French National Agency for Medicines and Health Products Safety (ANSM...
Sensorion Slides: Corporate presentation
Sensorion has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Sensorion Slides: Corporate presentation
Sensorion has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Sensorion Advances SENS-601 For GJB2 Hearing Loss And Discontinues SENS-501 Trials; Stock Down
(RTTNews) - Sensorion SA (ALSEN.PA), a biotechnology company, on Wednesday announced the selection of SENS-601 for treating GJB2-related hearing loss as the company's lead program, and the simultaneou...
Sensorion Appoints Fred Chereau CEO; CMO Geraldine Honnet Steps Down
(RTTNews) - Sensorion SA (ALSEN.PA), a French clinical-stage biotechnology company, on Monday announced that Chief Medical Officer Geraldine Honnet is stepping down to join a privately held biotechnol...
Sensorion Earnings release: H2 2025
Sensorion released its H2 2025 earnings on March 18, 2026, summarizing the period's financial results.
Sensorion Annual report: H2 2025
Sensorion has published its H2 2025 annual report on March 18, 2026.
Sensorion: CEO Nawal Ouzren To Resign
(RTTNews) - Sensorion (ALSEN.PA) announced that Nawal Ouzren, CEO and a Director, is stepping down from both posts due to a personal matter incompatible with serving as Chief Executive Officer. Amit M...